ライフサイエンスコーパス: SLL

1 In vitro studies were performed in Mec-1 SLL cells, which express both bcl-2 messenger RNA and so

2 S, proteinase-3-VLQ, PRAME-VLD, and NY-eso-1-SLL were isolated from HLA-A*02:01pos donors.

3 Only 3 PRAME-VLD-specific and one NY-eso-1-SLL-specific T-cell clone provoked interferon-gamma prod

4 rior lines of therapy) with an ORR of 47.3% (SLL, 67.9%; FL, 42.2%; MZL, 38.9%).

5 follows: MCL1, 38%; MCL2, 37%; IMC, 28%; and SLL, 14%.

6 her characteristics of patients with CLL and SLL differ in ways other than the absolute lymphocyte co

7 but controversy remains over whether CLL and SLL should be treated similarly.

8 l new treatment option for untreated CLL and SLL.

9 It was voluntarily withdrawn for FL and SLL accelerated approval indications coinciding with dec

10 and active therapeutic approach for NHL and SLL/CLL.

11 Despite complete pathologic remission at SLL after initial surgery and platinum-based chemotherap

12 lymphoma or B-small lymphocytic lymphoma (B-SLL) cell lines or patient samples.

13 Of 117 patients with CLL, SLL, or MCL who responded, all but eight remain progress

14 imilarly analyzed low-grade (12 MALT, 16 CLL/SLL) and high-grade (19 DLCL) lymphomas.

15 A total of 33 CLL/SLL patients were enrolled; only one patient discontinue

16 HR, 2.27; 95% CI, 1.34 to 3.84) or after CLL/SLL (n=49: HR, 2.92; 95% CI, 1.66 to 5.12).

17 ving initial chemotherapy, but not after CLL/SLL (SIR: CLL/SLL = 1.13, FL = 5.96, DLBCL = 4.96; P(Dif

18 risks were significantly elevated after CLL/SLL and FL but not after DLBCL (standardized incidence r

19 Melanoma risk after CLL/SLL was significantly increased among patients who recei

20 ute to the development of melanoma after CLL/SLL.

21 s of FL (OR = 1.4, 95% CI: 1.1, 1.9) and CLL/SLL (OR = 1.5, 95% CI: 1.1, 2.0) were mainly observed am

22 carcinoma, an EBV-associated cancer, and CLL/SLL forms of non-Hodgkin lymphomas; these cancers were a

23 e use may play a role in risks of FL and CLL/SLL in women who started use before 1980 and that increa

24 12 of 19) showed a loss of p27; MALT and CLL/SLL, however, were p27 positive.

25 d (P =.06) toward a difference between B-CLL/SLL and the lymphoplasmacytoid subtype.

26 as compared with that of patients with B-CLL/SLL, a significant difference was found (P <.

27 (Kiel classification) as a variant of B-CLL/SLL.

28 ing autoimmune diseases diagnosed before CLL/SLL (n=36: HR, 2.27; 95% CI, 1.34 to 3.84) or after CLL/

29 Among 2,126 consecutive CLL/SLL patients, 312 (15%) had ALC less than 5 x 10(9)/L.

30 from meat consumption increased risk for CLL/SLL alone.

31 LBCL and marginal zone lymphoma than for CLL/SLL and follicular lymphoma.

32 y lower rates than whites and blacks for CLL/SLL and Hodgkin lymphoma.

33 s were observed across strata of sex for CLL/SLL and marginal zone lymphoma subtypes as well as age f

34 In patients who were treated for CLL/SLL, the treatment regimen did not affect the risk of su

35 Overall response rates in CLL/SLL patients (n = 66) were 100%, 79%, and 71% in groups

36 MZL, whereas no response was observed in CLL/SLL patients.

37 sk, except for urinary tract infections (CLL/SLL), localized scleroderma, pneumonia, and gastrohepati

38 tic leukemia/small lymphocytic lymphoma (CLL/SLL) and 111 after other NHL subtypes (cumulative incide

39 tic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) represent indolent mal

40 tic leukemia/small lymphocytic lymphoma (CLL/SLL) but not for other NHL subtypes.

41 tic leukemia/small lymphocytic lymphoma (CLL/SLL) declined 2.1% per year.

42 tic leukemia/small lymphocytic lymphoma (CLL/SLL) was 1.66 (95% CI, 1.08-2.56; P = .02).

43 leukemia or small lymphocytic lymphoma (CLL/SLL) was the principal NHL subtype contributing to this

44 ic Leukaemia/Small Lymphocytic Lymphoma (CLL/SLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma

45 tic leukemia/small lymphocytic lymphoma (CLL/SLL).

46 tic leukemia/small lymphocytic lymphoma (CLL/SLL).

47 tic leukemia/small lymphocytic lymphoma (CLL/SLL).

48 tic leukemia/small lymphocytic lymphoma (CLL/SLL; HR, 0.84; 95% CI, 0.31 to 2.28).

49 tic leukemia/small lymphocytic lymphoma (CLL/SLL; N = 133).

50 tic leukemia/small lymphocytic lymphoma (CLL/SLL; n = 15), mantle cell lymphoma (MCL; n = 15), low-gr

51 xpressed on tumor cells in many cases of CLL/SLL (10 of 13 cases examined) with Mig expression less f

52 of developing NHL; however, the risk of CLL/SLL appears higher than for other NHL subtypes.

53 increase NHL risk, particularly risk of CLL/SLL, and are consistent with earlier studies relating lo

54 iated with the risk of NHL, particularly CLL/SLL.

55 ansformation (RT) and 8 with progressive CLL/SLL.

56 py, in patients with relapsed/refractory CLL/SLL.

57 proved in the United States for relapsed CLL/SLL and FL.

58 leukemia/small lymphocytic lymphoma (RR-CLL/SLL), irrespective of risk factors associated with poor

59 hemotherapy, but not after CLL/SLL (SIR: CLL/SLL = 1.13, FL = 5.96, DLBCL = 4.96; P(Diff) < .001).

60 ved for risk of cutaneous melanoma (SIR: CLL/SLL = 1.92, FL = 1.60, DLBCL = 1.06; P(Diff) = .004).

61 BCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL = 1.28, DLBCL = 1.00; Poisson regression

62 dent hematologic malignancies other than CLL/SLL.

63 rable safety profile in patients with TN CLL/SLL, regardless of the presence of TP53-aberrant disease

64 ged >=65 years with previously untreated CLL/SLL without del(17p) were randomly assigned to receive e

65 Patients with CLL/SLL have more than twice the risk of developing a second

66 PFS time of 18.6 months in patients with CLL/SLL seems shorter than the 36- to 40-month median PFSs p

67 In patients with CLL/SLL who failed to achieve a humoral response after stand

68 Of the 3,986 patients with CLL/SLL, 204 patients (5.1%) had possible RS, and 148 patien

69 ne ibrutinib treatment for patients with CLL/SLL, including those with high-risk genomic features.

70 he first-line treatment of patients with CLL/SLL, producing substantially higher response rates than

71 tment option for untreated patients with CLL/SLL.

72 ated with other cancers in patients with CLL/SLL.

73 usly untreated and treated patients with CLL/SLL.

74 s (cumulative incidence by age 85 years: CLL/SLL, 1.37%; other NHL subtypes, 0.78%).

75 omas, 4 CLL/small lymphocytic lymphomas (CLL/SLLs), and 1 low-grade NHL not otherwise specified.

76 0.011, R = 0.525), and knee abductors during SLL (IC: P = 0.021, R = 0.474) were positively correlate

77 .028, R = - 0.404), and hip extensors during SLL (TL: P = 0.006, R = - 0.5120) were negatively correl

78 Ankle plantar flexors during SLL (TL: P = 0.017, R = - 0.477) and DLL (TL: P = 0.028,

79 Knee extensors MEA during SLL (IC: P = 0.008, R = 0.522/TL: P < 0.001, R = 0.642)

80 d with less ankle plantar flexion MEA during SLL (IC: P = 0.027, R = - 0.514/TL: P = 0.007, R = - 0.6

81 responsive to prior treatments ( 1 MZL; 2 FL/SLL), including 1 anti-CD20-based therapy, were administ

82 BCL, 10% (2 of 21) for FL, 55% (6 of 11) for SLL/CLL, and 11% (1/9) for MCL.

83 MZL, 10.6 months for FL, and 20.9 months for SLL.

84 MZL, 11.1 months for FL, and 18.3 months for SLL.

85 eficiency) mice, a new animal model of human SLL.

86 l-2 expression in a new mouse model of human SLL.

87 nterfollicular small lymphocytic lymphoma (I-SLL) has not been well characterized and its relationshi

88 d immunophenotypic features of 13 cases of I-SLL and immunoglobulin heavy chain variable (VH) gene se

89 These studies support the proposal that I-SLL represents SLL/CLL and suggest the recently proposed

90 nterestingly, the mutational status of the I-SLL VH genes seemed to correlate with the two different

91 dence of ongoing mutation, consistent with I-SLL having either a naive or memory B cell origin.

92 in MCL and IMC but only limited activity in SLL.

93 In total, 20 of 30 (65%) included SLL and/or FL; 13 (42%) trials were completed, 13 (42%)

94 nding (TL) phases during single-leg landing (SLL), and double-leg landing (DLL).

95 ce of disease at the second-look laparotomy (SLL) procedure after primary chemotherapy.

96 ore the concept of structural Luneburg lens (SLL) as a design framework for performing dynamic struct

97 cytic leukemia/chronic lymphocytic leukemia (SLL/CLL).

98 that the gain increases and side-lobe-level (SLL) decreases.

99 r diagnosing instable scapholunate ligament (SLL) tears.

100 released into the seminiferous lobule lumen (SLL), where they develop into spermatozoa without direct

101 ytic leukemia or small lymphocytic lymphoma (SLL) and RR follicular lymphoma (FL) after two or more p

102 IMC), and small B-cell lymphocytic lymphoma (SLL) are B-cell malignancies that express CD20 and are i

103 ukemia (CLL) and small lymphocytic lymphoma (SLL) are currently considered the same entity, but contr

104 eukemia (CLL) or small lymphocytic lymphoma (SLL) enrolled in 4 early-phase trials were pooled.

105 eukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Br

106 relationship to small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL) is uncertain.

107 d MCL, three had small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL), and two had

108 nced for the CLL/small lymphocytic lymphoma (SLL) subtype (OR: 1.0; 3.2 [0.7-15.7]; 14.1 [1.9-103.2];

109 c leukemia (CLL)/small lymphocytic lymphoma (SLL) that was maintained at 24 hours.

110 efractory CLL or small lymphocytic lymphoma (SLL) to assess safety, pharmacokinetic profile, and effi

111 ukaemia (CLL) or small lymphocytic lymphoma (SLL) treated with a previous covalent BTK inhibitor (med

112 atients with CLL/small lymphocytic lymphoma (SLL) who failed to achieve a humoral response after stan

113 c leukemia (CLL)/small lymphocytic lymphoma (SLL) who presented at The University of Texas M.D. Ander

114 eukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse

115 a (NHL), such as small lymphocytic lymphoma (SLL), and many other cancers.

116 atients with CLL/small lymphocytic lymphoma (SLL), in a large population of patients with TP53-aberra

117 atients with CLL/small lymphocytic lymphoma (SLL), prolymphocytic leukemia, or Richter's transformati

118 c leukemia (CLL)/small lymphocytic lymphoma (SLL).

119 ymphoma (FL) and small lymphocytic lymphoma (SLL).

120 ukemia (CLL) and small lymphocytic lymphoma (SLL).

121 c leukemia (CLL)/small lymphocytic lymphoma (SLL).

122 of patients with small lymphocytic lymphoma (SLL)/B-cell chronic lymphocytic leukemia (B-CLL) treated

123 ttle activity in small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL) and to be associ

124 ormed FLs, four small lymphocytic lymphomas (SLL), two Waldenstrom's macroglobulinemias (WM), and one

125 ncluded 1 of 45 small lymphocytic lymphomas (SLLs), 2 of 38 follicular small cleaved-cell lymphomas (

126 trial, 202 eligible patients with a negative SLL were randomly selected to receive either 15 mCi IP 3

127 I epithelial ovarian cancer after a negative SLL.

128 tumor recurrence within 5 years of negative SLL.

129 d in five cadaveric wrists that had a normal SLL proved with dissection.

130 14 patients with an arthroscopically normal SLL and in five cadaveric wrists that had a normal SLL p

131 king advantage of the unique capabilities of SLL for flexural wave focusing and collimation, we devel

132 ame CD5-positive B cell phenotype typical of SLL or CLL.

133 structural wave cloak and waveguide based on SLLs.

134 our of 21 assessable patients responded (one SLL patient had a CR, one FL patient had a CR unconfirme

135 134 patients with relapsed/refractory CLL or SLL (median age, 66 years [range, 42-85 years]; median p

136 Patients with CLL or SLL can be treated similarly.

137 A total of 317 patients with CLL or SLL received pirtobrutinib, including 247 who had previo

138 Eligible patients had untreated CLL or SLL requiring treatment as per International Workshop on

139 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody

140 efficacy results among patients with CLL or SLL who had previously received a BTK inhibitor as well

141 y in patients with heavily pretreated CLL or SLL who had received a covalent BTK inhibitor.

142 electronic database for patients with CLL or SLL who presented to The University of Texas M.D. Anders

143 Among all 317 patients with CLL or SLL who received pirtobrutinib, the most common adverse

144 l responses in patients with relapsed CLL or SLL, including those with poor prognostic features.

145 y results among all the patients with CLL or SLL.

146 as frontline therapy in patients with CLL or SLL.

147 mong patients with previously treated CLL or SLL.

148 , or small lymphocytic lymphoma (MZL, FL, or SLL) unresponsive to prior treatments ( 1 MZL; 2 FL/SLL)

149 easured values of gain to 11.65 dBi, H-plane SLL to [Formula: see text] dB, and front-to-back ratio t

150 Although L and N at the -2 position (-SLL, -ANL) do not conform to the SKL motif, both functio

151 s support the proposal that I-SLL represents SLL/CLL and suggest the recently proposed two types of C

152 4, 99.5]), and 12 of 15 patients with stable SLLs were identified at cineradiography (specificity, 80

153 utive participants with clinically suspected SLL tears who underwent 4D CT from July 2020 to May 2022

154 The SLL design enables the integration of functional devices

155 The SLL is a graded refractive index lens, which is realized

156 ize the performance of the SLL cloak and the SLL waveguide.

157 ion of flatfish spermatids isolated from the SLL with rLh specifically promotes their differentiation

158 und to the Lhcgrba of free spermatids in the SLL, showing that circulating gonadotropin can reach the

159 he volar, middle, and dorsal portions of the SLL can be differentiated on the basis of MR appearance

160 d out to characterize the performance of the SLL cloak and the SLL waveguide.

161 he volar, middle, and dorsal portions of the SLL in 14 patients with an arthroscopically normal SLL a

162 The trapezoidal volar portion of the SLL was seen with inhomogeneous high intermediate signal

163 The results demonstrate that these SLL devices exhibit excellent performance for structural

164 Patients with SLL or CLL have yet to respond.